Stocks

Cipla gains over 2% on getting USFDA nod for multiple sclerosis drug

Internet Desk | Updated on September 25, 2020 Published on September 25, 2020

Drug major Cipla on Friday said it had received final approval from the US health regulator for Dimethyl Fumarate capsules, indicated for the treatment of relapsing forms of multiple sclerosis. The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc’s Tecfidera.

Cipla has received final approval for its abbreviated new drug application (ANDA) for Dimethyl Fumarate DR (delayed-release) capsules in the strengths of 120mg, 240mg and 120mg and 240mg from the United States Food and Drug Administration (USFDA), the company said in a regulatory filing.

Quoting IQVIA (IMS Health) data, Cipla said Tecfidera had US sales of approximately USD 3.8 billion for the 12 months ending July 2020.

Shares of Cipla were trading 2.12 per cent higher at ₹748.35 apiece on the NSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 25, 2020
This article is closed for comments.
Please Email the Editor